ストックスクリーナーアプリを入手
0.58
0.99%
-0.0058
アフターアワーズ：
.55
-0.03
-5.17%
前日終値:
$0.5858
開ける：
$0.6
24時間の取引高:
159.97K
Relative Volume:
1.36
時価総額：
$14.50M
収益：
-
当期純損益:
$-26.56M
株価収益率:
-0.8923
EPS:
-0.65
ネットキャッシュフロー:
$-22.29M
1週間 パフォーマンス:
+1.93%
1か月 パフォーマンス:
-10.08%
6か月 パフォーマンス:
-36.84%
1年 パフォーマンス:
-84.74%
1日の値動き範囲:
$0.5505
$0.6188
1週間の範囲:
$0.477
$0.70
52週間の値動き範囲:
$0.477
$4.99
BiomX Inc Stock (PHGE) Company Profile
名前
BiomX Inc
セクター
電話
972 7 23942377
住所
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.58 | 14.50M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-15 | 開始されました | Ladenburg Thalmann | Buy |
BiomX Inc (PHGE) 最新ニュース
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
Critical Audit Alert: BiomX Receives Going Concern OpinionWhat This Means - Stock Titan
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
BiomX Sets Major Double Update: Q4 Earnings Plus Crucial Phase 2 Osteomyelitis Data - Stock Titan
BiomX’s $12 Million Financing - Global Legal Chronicle
BiomX Inc. secures $12 million from recent offerings - Investing.com India
Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan
BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World
Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World
HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World
BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World
BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World
BiomX Inc (PHGE) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):